We are live on ! Find out more
RG

Redmile Group Portfolio holdings

AUM $1.49B Turnover 10.26%
1-Year Est. Return 208.7%
This Fund
S&P 500
This Quarter Est. Return
+15.59%
1 Year Est. Return
+208.7%
3 Year Est. Return
+777.5%
5 Year Est. Return
+1,114.43%
10 Year Est. Return
+23,630.52%
AUM
$664M
AUM Growth
+$96.5M
Cap. Flow
+$35.6M
Cap. Flow %
5.35%
Top 10 Hldgs %
45.17%
Holding
73
New
23
Increased
14
Reduced
10
Closed
23
Avg Time Held Equity + Options
0.1 years
Top 10 Avg Time Held Equity + Options
0.1 years
Top 20 Avg Time Held Equity + Options
0.1 years
Avg Time Held Equity only
0.1 years
Top 10 Avg Time Held Equity only
0.1 years
Top 20 Avg Time Held Equity only
0.1 years

Top Buys

Rank Stock Value
1
AMGN icon
Amgen
AMGN
+$37.5M
2
AGN
Allergan plc
AGN
+$36.2M
3
STJ
St Jude Medical
STJ
+$33.9M
4
GILD icon
Gilead Sciences
GILD
+$31.7M
5
CBST
CUBIST PHARMACEUTICALS INC
CBST
+$27.4M

Top Sells

Rank Stock Value
1
ALGN icon
Align Technology
ALGN
+$38.8M
2
ONXX
ONYX PHARMACEUTICALS INC
ONXX
+$34.2M
3
CAH icon
Cardinal Health
CAH
+$27.6M
4
IPXL
Impax Laboratories, Inc.
IPXL
+$19.2M
5
CELG
Celgene Corp
CELG
+$14.3M

Sector Composition

Rank Sector Weight
1 Healthcare 80.5%
2 Miscellaneous 17.62%
3 Consumer Staples 1.19%
4 Technology 0.69%
5 Communication Services 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
ARTC icon
26
DELISTED
ARTHROCARE CORP
ARTC
$12.2M 1.84%
+342,759
New +$12M
2013 Q3
0 quarters
TRNX
27
DELISTED
TORNIER N V SHARES (NLD)
TRNX
$11M 1.65%
568,100
+19,000
+3% +$353K
2013 Q2
1 quarter
KYTH
28
DELISTED
KYTHERA BIOPHARMACEUTICALS, INC COM
KYTH
$10.4M 1.57%
228,218
+118,100
+107% +$3.53M
2013 Q2
1 quarter
PACB icon
29
Pacific Biosciences
PACB
$619M
$8.71M 1.31%
1,574,379
-876,201
-36% -$3.04M
2013 Q2
1 quarter
TVTY
30
DELISTED
Tivity Health, Inc. Common Stock
TVTY
$8.57M 1.29%
+462,913
New +$8.37M
2013 Q3
0 quarters
NSTG
31
DELISTED
NanoString Technologies, Inc.
NSTG
$8.29M 1.25%
+754,132
New +$6.82M
2013 Q3
0 quarters
VRTX icon
32
Vertex Pharmaceuticals
VRTX
$126B
$8.21M 1.24%
+108,262
New +$8.61M
2013 Q3
0 quarters
ARAY icon
33
Accuray
ARAY
$20.9M
$7.93M 1.2%
+1,073,799
New +$6.79M
2013 Q3
0 quarters
WOOF icon
34
DELISTED
VCA Inc.
WOOF
$7.91M 1.19%
288,000
+10,000
+4% +$280K
2013 Q2
1 quarter
BSTC
35
DELISTED
BioSpecifics Technologies Corp.
BSTC
$6.36M 0.96%
326,652
+14,500
+5% +$257K
2013 Q2
1 quarter
FOLD icon
36
DELISTED
Amicus Therapeutics
FOLD
$5.74M 0.86%
2,473,787
+100,100
+4% +$251K
2013 Q2
1 quarter
NUWE icon
37
Nuwellis
NUWE
$1.68M
– –
0
– –
2013 Q3
0 quarters
PGEN icon
38
Precigen
PGEN
$2.64B
$4.82M 0.73%
+213,033
New +$4.92M
2013 Q3
0 quarters
VCRA
39
DELISTED
VOCERA COMMUNICATIONS, INC.
VCRA
$4.56M 0.69%
+245,400
New +$3.99M
2013 Q3
0 quarters
AMRN icon
40
Amarin Corp
AMRN
$245M
$4.11M 0.62%
+32,485
New +$3.89M
2013 Q3
0 quarters
GWPH
41
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$2.86M 0.43%
+165,020
New +$1.89M
2013 Q3
0 quarters
AGIO icon
42
Agios Pharmaceuticals
AGIO
$1.85B
$1.49M 0.22%
+53,100
New +$1.47M
2013 Q3
0 quarters
RCPT
43
DELISTED
RECEPTOS INC COM STK (DE)
RCPT
$540K 0.08%
+20,800
New +$400K
2013 Q3
0 quarters
VSTM icon
44
Verastem
VSTM
$698M
$386K 0.06%
+2,583
New +$451K
2013 Q3
0 quarters
PPH icon
45
VanEck Pharmaceutical ETF
PPH
$1.05B
$311K 0.05%
6,500
– –
2013 Q2
1 quarter
RPRX icon
46
DELISTED
Repros Therapeutics Inc.
RPRX
$281K 0.04%
+10,500
New +$225K
2013 Q3
0 quarters
AGN
47
DELISTED
Allergan Inc
AGN
$238K 0.04%
2,627
-124,400
-98% -$11.2M
2013 Q2
1 quarter
PRGO icon
48
Perrigo
PRGO
$2.21B
$210K 0.03%
+1,700
New +$212K
2013 Q3
0 quarters
MRK icon
49
Merck
MRK
$364B
$90K 0.01%
+1,991
New +$90.9K
2013 Q3
0 quarters
ABT icon
50
Abbott
ABT
$178B
– –
-7,200
Closed -$251K –
1
2
3

Similar funds

FCM
Fairholme Capital Management South Miami, Florida $1.49B AUM 28.35% 1-Year Est. Return
MM
Main Management San Francisco, California $1.49B AUM 22.28% 1-Year Est. Return
WA
WBH Advisory Baltimore, Maryland $1.49B AUM 20.41% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.49B AUM 32.81% 1-Year Est. Return
LCS
Levin Capital Strategies New York $1.49B AUM 30.44% 1-Year Est. Return
GAM
Gemmer Asset Management Walnut Creek, California $1.49B AUM 42.66% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $1.49B AUM 26.43% 1-Year Est. Return
PMG
ProVise Management Group Clearwater, Florida $1.49B AUM 21.79% 1-Year Est. Return

Redmile Group's Q3 2013 Portfolio in Review

As of Q3 2013, Redmile Group held 73 positions worth $664M, up 17% from $568M the previous quarter. Its ten largest holdings account for 45% of the portfolio.

Redmile Group deployed $35.6M of net new capital in Q3 2013, opening 23 new positions and adding to 14 existing holdings. Its largest new stake was Amgen: 345,700 shares worth $38.7M.

By sector, the portfolio is most concentrated in Healthcare at 80% of assets, down from 81% a quarter earlier, followed by Miscellaneous and Consumer Staples.

On the sell side, the largest reduction was Celgene Corp, an estimated $14.3M trimmed.

  • Redmile Group's largest Q3 2013 buy was Amgen: 345,700 shares worth $38.7M.
  • Redmile Group added most to Tenet Healthcare in Q3 2013, an estimated $11.5M increase.
  • Redmile Group's biggest Q3 2013 reduction was Celgene Corp, cutting an estimated $14.3M.
  • Redmile Group fully exited Align Technology in Q3 2013, selling an estimated $38.8M.
  • Redmile Group's ten largest holdings make up 45% of its $664M portfolio in Q3 2013.
  • Redmile Group opened 23 new positions and closed 23 in Q3 2013.
  • Redmile Group's portfolio value rose 17% quarter-over-quarter to $664M.

Based on Redmile Group's 13F filing for Q3 2013, filed 14 Nov 2013.